Core Viewpoint - The company plans to acquire 100% equity of Jiangsu Langyan Life Technology Holdings Co., Ltd. through the issuance of shares and convertible bonds, which aligns with the regulations of the Shanghai Stock Exchange's Sci-Tech Innovation Board [2][4] Group 1: Industry Alignment - The target company operates in the "C27 Pharmaceutical Manufacturing" sector, which is upstream and downstream related to the company's business, thus meeting the Sci-Tech Innovation Board's positioning requirements [2][3] - According to the National Bureau of Statistics, the target company's industry falls under the "4.1.2 Chemical Drugs and Raw Materials Manufacturing" category within the "4 Biological Industry," qualifying it as part of the biopharmaceutical field [3] Group 2: Synergy Between Companies - The company specializes in comprehensive preclinical and clinical drug research services (CRO) and has a demand for self-developed products, while the target company focuses on high-end chemical drugs and raw materials, having established a mature pharmaceutical production system [3] - The acquisition will enable the company to leverage the target's complete pharmaceutical production capabilities, enhancing research efficiency and reducing costs, while optimizing production processes and ensuring quality [3] - This transaction is expected to maximize the commercial value of the company's proprietary products and create new profit growth points by combining the research advantages of the company with the production and sales strengths of the target [3]

证券代码：688621 证券简称：阳光诺和 公告编号：2025-037 北京阳光诺和药物研究股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、关于非独立董事离职及选举职工代表董事的情况 公司董事会于近日收到公司非独立董事李文然先生递交的书面辞职报告，李 文然先生因个人原因申请辞去公司第二届董事会非独立董事职务。李文然先生离 任后将不在公司以及子公司担任其他职务。截至本公告日，李文然先生未持有公 司股票，不存在应当履行而未履行的承诺事项。公司及董事会对李文然先生在任 期间的辛勤付出和贡献表示衷心感谢。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交 易所科创板股票上市规则》及新修订的《公司章程》等有关规定，公司董事会由 工代表大会选举产生，直接进入董事会。 公司于2025年5月12日召开第三次职工代表大会，经与会职工表决通过，同 意选举张金凤女士（简历附后）为公司第二届董事会职工代表董事，本次职工代 表大会选举产生的1名职工代表董事将与公司8名非职工代表董事共同组成公司 第二届董事会，任期 ...

Core Viewpoint - The company confirms that it does not fall under any prohibitive conditions outlined in the "Regulations on the Administration of Securities Issuance Registration of Listed Companies" regarding the issuance of shares to specific targets or convertible bonds [1][2] Summary by Relevant Sections Section 1: Conditions for Issuing Shares - The company has not changed the use of previously raised funds without correction or shareholder approval [1] - The financial statements for the past year comply with accounting standards and disclosure rules, with no adverse audit opinions [1] - Current directors and senior management have not faced administrative penalties from the China Securities Regulatory Commission (CSRC) in the last three years [1] - There are no ongoing criminal investigations or regulatory inquiries against the company or its current management [1] - The controlling shareholder or actual controller has not engaged in significant illegal activities harming the company's interests in the last three years [1] - There are no major illegal activities in the last three years that have severely harmed investors' rights or public interests [1] Section 2: Conditions for Issuing Convertible Bonds - The company has no ongoing defaults or delayed payments on previously issued bonds or debts [1] - There have been no violations of the Securities Law regarding the change of use for funds raised from publicly issued bonds [1]

Group 1 - The company plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Holdings Co., Ltd. through the issuance of shares and convertible bonds, while also raising matching funds from no more than 35 specific investors [3] - The company's stock was suspended from trading starting April 25, 2025, due to the planned asset acquisition and fundraising activities [3][4] - The stock is scheduled to resume trading on May 13, 2025, after the completion of relevant audits and evaluations [4] Group 2 - The board of directors has decided not to hold a shareholders' meeting to review the transaction until the audit and evaluation work is completed [4] - The company will continue to fulfill its information disclosure obligations in accordance with relevant laws and regulations after the stock resumes trading [4][5] - All information regarding the transaction will be disclosed through the Shanghai Stock Exchange website and designated media [5]

Core Viewpoint - Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. plans to deregister its subsidiary Nanjing Nuohexin Pharmaceutical Technology Co., Ltd. to optimize internal management and reduce operational costs [1][2] Group 1: Company Overview - The company is proposing to deregister its controlling subsidiary Nanjing Nuohexin, which is considered a related transaction but does not constitute a major asset restructuring [1][2] - Zhao Lingyang, who held various positions in the company from January 2019 to September 2024 and owns 18% of Nuohexin, is identified as a related party [2][3] Group 2: Financial Information - Nuohexin's total assets as of December 31, 2024, were approximately 10.14 million yuan, up from about 8.74 million yuan in 2023, indicating a growth of approximately 15.98% [4] - The total liabilities of Nuohexin increased from approximately 872,784.84 yuan in 2023 to about 9.19 million yuan in 2024, reflecting a significant rise [4] - Nuohexin reported a total revenue of approximately 7.60 million yuan in 2024, with a net loss of about 6.92 million yuan, compared to a net loss of approximately 3.23 million yuan in 2023 [5] Group 3: Reasons for Deregistration - The decision to deregister Nuohexin is based on the company's development plan and the operational status of the subsidiary, aiming to streamline management and enhance operational efficiency [2][5] - After deregistration, the core business and employees of Nuohexin will be managed by its controlling shareholder, ensuring a smooth transition and protection of employee rights [5] Group 4: Impact of Deregistration - The proposed deregistration is not expected to have a significant impact on the overall business development and profitability of the company, although it will change the scope of the consolidated financial statements [5]

Core Viewpoint - The company plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through the issuance of shares and convertible bonds, which aligns with relevant regulations and policies [1][2][7]. Compliance with Regulations - The transaction complies with national industrial policies and relevant laws regarding environmental protection, land management, anti-monopoly, foreign investment, and outbound investment [1][2]. - The transaction does not require prior approval from the Ministry of Commerce as it does not meet the concentration declaration standards [2]. - The transaction will not affect the company's compliance with stock listing conditions, as the public shareholding ratio will remain above 25% post-transaction [2][3]. Asset Valuation and Legality - The asset pricing is fair and does not harm the company's or shareholders' legal rights, with an independent evaluation process in place [3][4]. - The ownership of the assets is clear, and there are no legal obstacles to the transfer of ownership [4][5][10]. Business Synergy and Growth Potential - The acquisition is expected to enhance the company's operational capabilities by leveraging its R&D strengths alongside Langyan's production and sales advantages, creating new profit growth points [5][11]. - The transaction will expand the company's business into the pharmaceutical industrial sector, establishing a "CRO + pharmaceutical industry" layout that is anticipated to improve profitability and risk resistance [5][7]. Independence and Governance - The company maintains independence from its controlling shareholders in terms of business, assets, finance, personnel, and institutions, complying with relevant regulations [6][8]. - The company has a sound corporate governance structure, ensuring compliance with laws and regulations post-transaction [6][7]. Financial Health and Compliance - The company has received a standard unqualified audit report for the last fiscal year, indicating no issues with financial reporting [8][9]. - The transaction will reduce related party transactions and avoid competition with the controlling shareholder's other enterprises, enhancing the company's independence [7][8].

根据相关法律法规的要求，公司董事会对公司股票价格在本次交易首次公告 日前 20 个交易日内波动情况进行了自查，结果如下：公司股票（证券简称：阳 光诺和，证券代码：688621）自 2025 年 4 月 25 日开市起停牌，本次停牌前一交 易日（2025 年 4 月 24 日），公司收盘价格为 45.97 元/股，停牌前第 21 个交易 日（2025 年 3 月 26 日）收盘价格为 41.86 元/股。 本次停牌前 20 个交易日内股票价格波动情况，以及该期间大盘及行业指数 波动情况的自查情况如下： 股价/指数 2025 年 3 月 26 日收盘价 2025 年 4 月 25 日收盘价 涨跌幅 公司股票收盘价 （元/股） 科创 50 指数 （000688.SH） 万得 CRO 指数 （866135.WI） 北京阳光诺和药物研究股份有限公司董事会 关于公司股票价格在本次交易首次公告日前 20 个交易日内 波动情况的说明 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"上市公司"） 拟通过发行股份及支付可转换公司债券购买江苏朗研生命科技控股有限公司（以 下简称"朗研生命"）100%股权，并向不超过 35 名 ...

北京阳光诺和药物研究股份有限公司董事会 第十三条规定的重组上市情形的说明 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"上市公司"） 拟通过发行股份及可转换公司债券方式购买江苏朗研生命科技控股有限公司（以 下简称"朗研生命"）100%股权，并向不超过 35 名特定投资者发行股份募集配 套资金（以下简称"本次交易"）。 公司董事会经认真对照《上市公司重大资产重组管理办法》的相关规定并经 审慎判断，认为本次交易不构成《上市公司重大资产重组管理办法》第十三条规 定的重组上市情形，具体情况如下： 一、关于重组上市的规定 《上市公司重大资产重组管理办法》第十三条第一款规定："上市公司自控 制权发生变更之日起三十六个月内，向收购人及其关联人购买资产，导致上市公 司发生以下根本变化情形之一的，构成重大资产重组，应当按照本办法的规定履 行相关义务和程序： （二）购买的资产在最近一个会计年度所产生的营业收入占上市公司控制权 发生变更的前一个会计年度经审计的合并财务会计报告营业收入的比例达到百 分之一百以上； （三）购买的资产净额占上市公司控制权发生变更的前一个会计年度经审计 的合并财务会计报告期末净资产额的比例达到百分 ...

北京阳光诺和药物研究股份有限公司 2025 年限制性股票激励计划实施考核管理办法 北京阳光诺和药物研究股份有限公司 为了进一步健全公司长效激励机制，吸引和留住优秀人才，充分调动公司员 工的积极性，有效地将股东利益、公司利益和核心团队个人利益结合在一起，使 各方共同关注公司的长远发展，在充分保障股东利益的前提下，按照收益与贡献 匹配的原则，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上海证券交易所科创板股 票上市规则》（以下简称"《上市规则》"）《上市公司股权激励管理办法》（以 下简称"《管理办法》"）《科创板上市公司自律监管指南第 4 号——股权激励 信息披露》（以下简称"《监管指南第 4 号》"）等有关法律法规、规章和规范 性文件以及《北京阳光诺和药物研究股份有限公司公司章程》（以下简称"《公 司章程》"）的规定，公司制定了北京阳光诺和药物研究股份有限公司 2025 年 限制性股票激励计划（以下简称"本次激励计划"）。 为保证本次激励计划的顺利实施，根据《公司法》《证券法》《管理办法》 《监管指南第 4 号》等有关法律法规和规范性文件以及《公司 ...

北京阳光诺和药物研究股份有限公司 北京阳光诺和药物研究股份有限公司（以下简称"公司"）第二届董事会独 立董事专门会议第六次会议于 2025 年 5 月 12 日在北京以现场与通讯相结合的方 式召开。会议应出席独立董事 3 人，实际出席独立董事 3 人。本次会议的召开符 合《中华人民共和国公司法》《上市公司独立董事管理办法》等法律、法规及《北 京阳光诺和药物研究股份有限公司章程》的有关规定。 经与会独立董事审议，同意公司拟通过发行股份及可转换公司债券方式购买 江苏朗研生命科技控股有限公司 100%股权，并向不超过 35 名特定投资者发行股 份募集配套资金（以下简称"本次交易"）相关议案并同意提交公司第二届董事 会第十九次会议审议，现发表审核意见如下： 市公司重大资产重组管理办法》《上海证券交易所上市公司重大资产重组审核规 则》 《上市公司证券发行注册管理办法》 《上市公司向特定对象发行可转换公司债 券购买资产规则》等法律、法规和规范性文件关于发行股份及可转换公司债券购 买资产并募集配套资金的规定。 议通过，关联董事回避表决。本次董事会的召集和召开程序、表决程序及方式符 合相关法律、法规及公司章程的规定。根据《上 ...